Advances in combined immunotherapy for sepsis

Abstract

Sepsis is a serious life-threatening multiple organ dysfunction disease with high morbidity and mortality, how to conquer sepsis is a worldwide problem. According to the latest international consensus, the occurrence of sepsis is associated with the host's immune response, so reasonable and accurate use of immune regulating scheme for comprehensive treatment of sepsis will be the research hot spot. The pathogenesis of sepsis can be simply divided into the stage of systemic inflammatory response and stage of compensatory anti-inflammatory response, corresponding immune regulating measures are anti-inflammatory therapy and immunostimulation therapy respectively. Although immunotherapy has reduced the mortality of patients to some extent, how to maximize the survival rate of sepsis patients is still a difficulty. Currently, immune combined therapy is carried out widely in the field of cancer treatment, and the therapeutic effect is significant, but in the field of sepsis, immune combined therapy research is less. This article summarizes the recent 10 years' advances in immune combined therapy for sepsis, including the combination between glucocorticoid, that between interleukin and immune checkpoint inhibitor, and that between both Chinese medicine Xuebijing injection and thymosin alpha 1 and other drugs, etc. Immune combined therapy has achieved initial success in the field of sepsis, and shows a great potential and development space. It is believed that in the near future, immune combined therapy is expected to become a new therapeutic strategy and bring breakthrough for the treatment of sepsis.